STING1 and neoplasm: Numerous preclinical studies using synthetic STING agonists have now shown that targeted activation of the STING pathway within established murine tumors can shift the immune profile of an immunosuppressive tumor microenvironment (TME) toward an immunogenic state that is conducive to productive antitumor immunity and to enhancing the therapeutic efficacy of multiple immunotherapeutic modalities (21, 27, 28).